Page contents Key factsDecisionRelated medicine informationKey facts Invented name Ilaris Active Substance Canakinumab Therapeutic area Immunology-Rheumatology-Transplantation Decision number P/0366/2019 PIP number EMEA-000060-PIP07-19 Pharmaceutical form(s) Powder for solution for injectionSolution for injection Condition(s) / indication(s) Treatment of gout Route(s) of administration Subcutaneous use Contact for public enquiries Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 07/11/2019DecisionP/0366/2019: EMA decision of 7 November 2019 on the granting of a product specific waiver for canakinumab (Ilaris), (EMEA-000060-PIP07-19)AdoptedReference Number: EMA/588311/2019 English (EN) (179.32 KB - PDF)First published: 27/03/2020ViewRelated medicine informationIlarisShare this page